KashinathGangadharaYadalamMD

Clinical Trials

• A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) Start of enrollment: 2011 Feb 01

  Completed

  Phase 2, Phase 3

• Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia Start of enrollment: 2011 Jul 01

  Completed

  Phase 3

• Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia Start of enrollment: 2011 Sep 01

  Completed

  Phase 3

• PEARL Schizophrenia Maintenance Start of enrollment: 2011 Sep 01

  Completed

  Phase 3

• AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01

  Completed

  Phase 2, Phase 3

• Pediatric Schizophrenia Efficacy and Safety Study Start of enrollment: 2013 Aug 01

  Completed

  Phase 3

• Lurasidone Pediatric Autism Study Start of enrollment: 2013 Aug 01

  Completed

  Phase 3

• Lurasidone Pediatric Bipolar Study Start of enrollment: 2014 Mar 01

  Completed

  Phase 3

• Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients Start of enrollment: 2014 Apr 01

  Completed

  Phase 3

• Open-label Safety Study in Adults With ADHD Start of enrollment: 2014 Jun 01

  Completed

  Phase 3

• A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease Start of enrollment: 2016 Jun 01

  Terminated

  Phase 3

• Join now to see all